PMI SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Picard Medical (PMI) Investors of Securities Class Action Deadline on April 13, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses Exceeding $50,000 In Picard Medical To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in [Picard Medical] between September 2, 2025 and October 31, 2025 and would like to ...

PYPL SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds PayPal (PYPL) Investors of Securities Class Action Deadline on April 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses Exceeding $50,000 In PayPal To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in [PayPal] between February 25, 2025 and February 2, 2026 and would like to discuss your legal rig ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against uniQure N.V. and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against uniQure - The complaint alleges that uniQure and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose that the design of uniQure's Pivotal Study was not fully approved by the FDA [1] - Defendants downplayed the likelihood that uniQure would have to delay its Biologics License Application (BLA) timeline to perform additional studies, despite purportedly successful results from the Pivotal Study [1] - As a result, the statements made by Defendants regarding the company's business, operations, and prospects lacked a reasonable basis [1] Group 2: Impact of FDA Disclosure - On November 3, 2025, uniQure disclosed that the FDA "currently no longer agrees" that data from the Phase I/II AMT-130 studies would be adequate to support a BLA submission [1] - The company admitted that the timing of any BLA submission for AMT-130 was now unclear, revealing the falsity of prior representations that AMT-130 was on a near-term path toward accelerated approval [1] - Following this disclosure, uniQure's ordinary share price fell by $33.40 per share, or more than 49%, from a close of $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [1]

ARDT SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ardent Health (ARDT) Investors of Securities Class Action Deadline on March 9, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses Exceeding $50,000 In Ardent To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in [Ardent] between July 18, 2024 and November 12, 2025 and would like to discuss your legal ...

Core Viewpoint - Analog Devices, Inc. will participate in the Morgan Stanley Technology, Media, and Telecom Conference, highlighting its role in the semiconductor industry and discussing business trends [1] Group 1: Company Participation - The Executive Vice President & Chief Financial Officer, Richard Puccio, will present at the conference on March 3, 2026, at 10:00 a.m. PST [1] - The conference will be accessible via a live webcast on the Investor Relations section of Analog Devices' website, with an archived replay available for at least 30 days [1] Group 2: Company Overview - Analog Devices, Inc. is a global leader in semiconductors, focusing on bridging the physical and digital worlds to enable advancements at the Intelligent Edge [1] - The company integrates analog, digital, AI, and software technologies to address challenges such as climate change and to enhance automation, robotics, mobility, healthcare, energy, and data centers [1] - In FY25, Analog Devices reported revenue exceeding $11 billion, positioning itself as a key player in innovation [1]

Kyndryl Holdings (KD) Files Amended Quarterly and Fiscal Year Reports Detailing Material Internal Control Weaknesses After 3 Key Executives Depart, Securities Class Action Pending- Hagens Berman [Accessibility Statement] Skip NavigationSAN FRANCISCO, Feb. 20, 2026 /PRNewswire/ -- On February 17, 2026, Kyndryl Holdings, Inc. (NYSE: KD) filed two amended quarterly reports and one amended annual report providing further detail about problems previously reported on February 9, 2026.The recent filings reveal tha ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential securities class action claims against Enphase Energy, Inc. due to allegations of false and misleading statements regarding the company's financial and operational prospects [1] Group 1: Allegations Against Enphase - The complaint alleges that Enphase overstated its ability to manage channel inventory [1] - It is claimed that Enphase overstated its ability to mitigate effects from the termination of the 25D Credit [1] - The company is accused of making materially false and misleading public statements regarding its financial and operational prospects [1] Group 2: Financial Impact - On October 28, 2025, Enphase reported weak financial results for Q3 2025, indicating elevated channel inventory and lower battery storage shipments expected for Q4 2025 [1] - The expiration of the residential solar investment tax credit is anticipated to negatively impact revenues for Q1 2026 [1] - Following the earnings report, Enphase's stock price fell by $5.56 per share, or 15.15%, closing at $31.14 per share on October 29, 2025 [1] Group 3: Legal Proceedings - Investors who suffered losses exceeding $50,000 between April 22, 2025, and October 28, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights [1] - The deadline to seek the role of lead plaintiff in the class action is April 20, 2026 [1] - Any member of the putative class may move the Court to serve as lead plaintiff or remain an absent class member without affecting their ability to share in any recovery [1]

SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Reminds NuScale (SMR) Investors of Securities Class Action Deadline on April 20, 2026 [Accessibility Statement] Skip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner [James (Josh) Wilson] Encourages Investors Who Suffered Losses In NuScale To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in [NuScale] between May 13, 2025 and November 6, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Endeavor Group Holdings, Inc. (EDR) and reminds investors of the March 18, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Legal Action and Allegations - The complaint alleges that Endeavor and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose critical information in the January 15, 2025 Information Statement and related SEC filings [1][1] - Specific allegations include misleading investors about the true value of Endeavor's shares, inadequate disclosure of executive earnings under the terms of the Merger, and undisclosed conflicts of interest involving Endeavor's special committee and financial advisor [1][1] Group 2: Class Action Participation - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who is also typical of class members and oversees the litigation on their behalf [1] - Any member of the putative class can move the Court to serve as lead plaintiff through their chosen counsel or may choose to remain an absent class member without affecting their ability to share in any recovery [1][1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Pomdoctor Limited (NASDAQ: POM) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action filed against the company [1] Group 1: Allegations Against Pomdoctor - The complaint alleges that Pomdoctor and its executives violated federal securities laws by making false and/or misleading statements and failing to disclose critical information [1] - Specific allegations include involvement in a fraudulent stock promotion scheme, use of offshore accounts for share dumping, and omission of false rumors affecting stock price [1] - The company's public statements were deemed materially misleading and lacked a reasonable basis due to these omissions [1] Group 2: Stock Performance - Pomdoctor's share price experienced a significant decline from approximately $0.50 per share on December 10, 2025, to about $0.38 per share on December 11, 2025, marking a decline of roughly $0.12 per share or approximately 24% in a single trading session [1] - This decline followed increased volatility and selling pressure amid broader investor concerns regarding Pomdoctor's financial performance and valuation [1] Group 3: Legal Proceedings - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought by the class, who will oversee the litigation on behalf of the class members [1] - Any member of the putative class may move the Court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [1]